Abstract
Traditionally, abstinence has been regarded as the only appropriate goal in the treatment of alcohol dependence in Japan. Recently, harm reduction by reducing alcohol consumption, which has been used as a treatment approach in Europe, has gained recognition in Japan. The 2018 guideline for the treatment of alcohol dependence in Japan recommends abstinence as the primary goal, but reduction of alcohol consumption is described as an appropriate treatment goal in some patients. Nalmefene is an opioid modulator that is used to reduce alcohol consumption in patients with alcohol dependence. Here, we report the clinical course of alcoholic liver cirrhosis in alcohol-dependent patients who were treated with nalmefene for three months. Their alcohol consumption was reduced, which led to an improvement in liver function. Nalmefene provides a clinical benefit, constitutes a potential pharmacological treatment paradigm in terms of the treatment goal and dosing regimen, and addresses an unmet medical need in patients with alcohol dependence who need to reduce their alcohol consumption.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
